Actively Recruiting
Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction
Led by Haiyan Wang · Updated on 2024-01-09
438
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to evaluating myocardial stiffness in patients with heart failure with preserved ejection fraction (HFpEF) by intrinsic wave velocity propagation (IVP). The main questions it aims to answer are: * Whether myocardial stiffness assessed by IVP in patients with HFpEF Increased. * Whether IVP is related to the cardiac structure and function in patients with HFpEF. * What are the risk factors that may be associated with heart failure rehospitalization in patients with HFpEF? * Whether increased myocardial stiffness is a risk factor for heart failure rehospitalization. Participants will undergo transthoracic echocardiography to obtain conventional ultrasound parameters, and software post-processing analysis to obtained two-dimensional strain parameters and IVP, as well as general clinical data and laboratory test results. Clinical followed up was performed through electronic medical records or telephone interviews until patient rehospitalization for heart failure or discharge for one year.
CONDITIONS
Official Title
Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the diagnostic criteria for HFpEF according to 2022 AHA/ACC/HFSA Guidelines
- Present with signs and symptoms of heart failure
- Have left ventricular ejection fraction (LVEF) of 50% or higher
- Have at least one additional criterion: increased BNP (≥35 pg/ml) or NT-pro BNP (>125 pg/ml), resting or stress echocardiography E/e' ≥15, cardiac catheterization with PCWP ≥15 mmHg or LVEDP ≥16 mmHg, or PCWP at peak exercise ≥25 mmHg
- Age between 18 and 80 years
You will not qualify if you...
- Acute coronary syndrome, acute heart failure, or coronary revascularization within 3 months
- Heart failure with improved ejection fraction, cardiomyopathy, severe valvular heart disease, or arrhythmia
- Thyroid dysfunction, pulmonary hypertension, past or current pulmonary embolism
- Severe chronic obstructive pulmonary disease
- Malignancy or renal failure with estimated glomerular filtration rate less than 30 ml/min
- Poor quality of echocardiogram images
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China, 250000
Actively Recruiting
Research Team
H
Haiyan Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here